Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence

Figure 6

The meta-analysis results for progression-free survival (PFS) among groups after afatinib treatment in advanced NSCLC with EGFR mutation: (a) PFS between non-full-dose group and full-dose group; (b) PFS between the full-dose group and non-full-dose group; and (c) the OS between non-full-dose group and full-dose group in advanced NSCLC patients with epidermal growth factor receptor (EGFR) positive mutations after afatinib treatment.

(a)

(b)

(c)